Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 11, 2001, Pages 645-652

  Chatzistamou, Ioulia ^a   Schally, Andrew V ^a   Varga, Jozsef L ^a   Groot, Kate ^a   Armatis, Patricia ^a   Bajo, Ana ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antagonists; GH RH; Ovarian cancer; Tumorigenicity; VIP

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; JV 136; JV 152; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INOCULATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0034793313     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320100254     Document Type: Article

References (38)

1. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity
2. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit growth of OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice
3. Inhibition of growth, production of insulin-like growth factor-II (IGF-II) and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
4. Frequent loss of heterozygosity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors
5. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
6. Characterization and development of UCI-107: A primary human ovarian carcinoma cell line
7. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone
8. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
9. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma
10. Expression of growth hormone-releasing hormone (GH-RH) messenger ribonucleic acid and the presence of biologically active GH-RH in human breast, endometrial, and ovarian cancers
11. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB468 estrogen - Independent human breast cancers in nude mice
12. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone
13. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
14. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice
15. Antitumorigenic actions of growth hormone-releasing hormone antagonists
16. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
17. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors
18. Cancer Statistic
19. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75)
20. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo
21. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone releasing hormone
22. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
23. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
24. Inhibition of growth of small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH)
25. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways
26. Inhibition of growth of transplantable rat chondrosarcoma by analogs of hypothalamic hormones
27. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers
28. Antagonistic actions of analogs related to growth hormone-releasing hormone (GH-RH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro
29. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers
30. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging
31. Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents
32. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate
33. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors
34. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
35. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
36. VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor
37. Expression of insulin-like growth factor (IGF) IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries
38. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist